Metagenomi Therapeutics (MGX) Accumulated Expenses (2023 - 2026)

Metagenomi Therapeutics (MGX) has reported Accumulated Expenses for 4 consecutive years, with $4.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses fell 23.37% year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $4.7 million (down 23.37% YoY), while the FY2025 annual figure was $6.7 million, down 20.22% from the prior year.
• Accumulated Expenses declined to $4.7 million in Q1 2026 per MGX's latest filing, from $6.7 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $11.5 million in Q4 2023 and bottomed at $4.7 million in Q1 2026.
• Historically, Accumulated Expenses has averaged $8.0 million across 4 years, with a median of $7.8 million in 2024.
• On a YoY basis, Accumulated Expenses climbed as much as 11.96% in 2025 and fell as far as 46.07% in 2025.
• Metagenomi Therapeutics' Accumulated Expenses stood at $11.5 million in 2023, then slipped by 26.59% to $8.4 million in 2024, then fell by 20.22% to $6.7 million in 2025, then slumped by 30.2% to $4.7 million in 2026.
• Business Quant data shows MGX's Accumulated Expenses at $4.7 million in Q1 2026, $6.7 million in Q4 2025, and $9.9 million in Q3 2025.